表紙
市場調查報告書

氣喘及COPD治療藥市場 - 成長,趨勢,預測(2019年∼2024年)

Asthma and COPD Drugs Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 866753
出版日期 內容資訊 英文 115 Pages
商品交期: 2-3個工作天內
價格
Back to Top
氣喘及COPD治療藥市場 - 成長,趨勢,預測(2019年∼2024年) Asthma and COPD Drugs Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年06月01日內容資訊: 英文 115 Pages
簡介

預計全球氣喘及COPD治療藥市場在2019年∼2024年間,預測將以4.2%的年複合成長率擴大。

本報告提供氣喘及COPD治療藥的世界市場調查,市場概要,各類型,各地區的市場趨勢,市場規模的變化與預測,市場促進、阻礙因素以及市場機會分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 成長要素
  • 阻礙因素
  • 波特的五力分析
    • 新加入廠商的威脅
    • 消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭

第5章 市場區隔

  • 各類藥品
    • 支氣管擴張藥
    • 抗發炎藥
    • 單株抗體
    • 並用藥
  • 各症狀
    • 氣喘
    • 慢性阻塞性肺病
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東&非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • AstraZeneca
    • Boehringer Ingelheim
    • GlaxoSmithKline
    • Grifols
    • Merck & Co.
    • Pfizer
    • Roche Holding AG
    • Sumitomo Dainippon Pharma
    • Teva Pharmaceutical

第7章 市場機會及未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 55752

Market Overview

The asthma and COPD drugs market is expected to witness a CAGR of 4.2% during the forecast period. Certain factors that are driving the market growth include increase in incidence and prevalence of asthma and COPD, technological advancements, and growing geriatric population.

  • The global population is aging rapidly, owing to reduced birth rates and increasing life expectancy. According to the US Census Bureau's Statistics, as of 2017, the total number of people aged between 65 years and older, exceeded 50 million. According to the United Nations, during the period of 2015-2030, the number of older persons aged 60 years or over, worldwide, is projected to grow by 56% (from 901 million to more than 1.4 billion).
  • Moreover, economic and social commission for Asia and the Pacific (ESCAP), reports that the geriatric population in Asia-Pacific was around 617.1 million in 2015, accounting for more than half of the world's total elderly population. It is estimated that, by 2050, Asia-Pacific may account for almost two-thirds of the world's geriatric population. Hence, owing to the fact that asthma is a widely prevalent disease found in people over age 65, the growing geriatric population is expected to drive the market growth over the forecast period.

Scope of the Report

Asthma is a chronic respiratory disease, which blocks the airways of the lung because of mucus production, inflammation, and tightening of muscles. Similarly, chronic obstructive pulmonary disease (COPD) is caused by the blockade in the airways, further resulting in difficulty in breathing. Asthma and COPD drugs are the drugs which are used to treat these aforementioned respiratory diseases.

Key Market Trends

Asthma is Expected to Hold the Largest Market Share in the Indication Type

According to the American Academy of Allergy Asthma and Immunology (AAAI), in 2016, approximately 8.3% of children in the United States were found to have asthma. Boys were to some extent more likely to have asthma than girls at a rate of 9.2% and 7.4%, respectively. Asthma incidence among children increased from 8.7% in 2001 to 9.4% in 2010, and then declined to 8.3% in 2016. Although not all changes were statistically noteworthy, a similar outline was observed among the sub-demographic groups, except the Mexican/Mexican-American children, among whom asthma prevalence increased from 5.1% in 2001 to 6.5% in 2016.

North America Dominates the Market and Expected to do Same in the Forecast Period

According to the AAAI, in 2012, the median annual medical cost of asthma was USD 983 in the United States. This ranged from an average low of USD 833 in Arizona to an average high of USD 1,121 in Michigan. In addition, there were 3,615 asthma-related deaths in 2015. Children under 18 years old made up 219 of those deaths. Asthma prevalence was the highest among workers in the healthcare and social assistance industry, with 8.8% of workers stating that they had asthma at the time of the survey. Workers in the educational services industry reported the second-highest rate (8.2%) of asthma prevalence. Hence, the growing prevalence of asthma is expected to contribute to the significant market share of the North American market over the forecast period.

Competitive Landscape

The asthma and COPD drugs market is highly competitive and consists of few major players. Companies, like Abbott Laboratories, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck & Co., Grifols, Novartis AG, Pfizer, Roche Holding AG, and Teva Pharmaceutical, among others, hold the substantial market share in the asthma and COPD drugs market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increase in Incidence and Prevalence of Asthma and COPD
    • 4.2.2 Technological Advancements
    • 4.2.3 Growing Geriatric Population
  • 4.3 Market Restraints
    • 4.3.1 Stringent Government Regulations for the Product Approval
    • 4.3.2 Side Effects Associated with Drugs
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug Class
    • 5.1.1 Bronchodilators
      • 5.1.1.1 Short Acting Beta-2 Agonists
      • 5.1.1.2 Long Acting Beta-2 Agonists
      • 5.1.1.3 Anti-cholinergic Agents
    • 5.1.2 Anti-inflammatory Drugs
      • 5.1.2.1 Oral and Inhaled Corticosteroids
      • 5.1.2.2 Anti-leukotrienes
      • 5.1.2.3 Phosphodiesterase Type-4 Inhibitors
      • 5.1.2.4 Other Anti-inflammatory Drugs
    • 5.1.3 Monoclonal Antibodies
    • 5.1.4 Combination Drugs
  • 5.2 By Indication
    • 5.2.1 Asthma
    • 5.2.2 Chronic Obstructive Pulmonary Disease
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AstraZeneca
    • 6.1.2 Boehringer Ingelheim
    • 6.1.3 GlaxoSmithKline
    • 6.1.4 Grifols
    • 6.1.5 Merck & Co.
    • 6.1.6 Pfizer
    • 6.1.7 Roche Holding AG
    • 6.1.8 Sumitomo Dainippon Pharma
    • 6.1.9 Teva Pharmaceutical

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top